Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Onychomycosis
Interventions: Albaconazole tablet 400mg, Albaconazole 100mg capsules, then albaconazole 400mg tablet; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Developmental Language Disorder, Speech Sound Disorder, Specific Language Impairment
Interventions: Sensitivity to phonological rules, Sensitivity to semantic category cues.; Other
Lead sponsor: Father Flanagan's Boys' Home; Other
Eligibility: 4 Years to 8 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Tucson, Arizona • Omaha, Nebraska

Conditions: Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Interventions: RO7566802, Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • New Haven, Connecticut • New York, New York + 3 more

Conditions: Compartment Syndrome of Leg, Healthy
Interventions: Mepivacaine Injection; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: CYB003; Drug
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 42
States / cities: Phoenix, Arizona • Glendale, California • La Jolla, California + 32 more

Conditions: Chronic Graft Versus Host Disease, cGVHD
Interventions: Axatilimab, Extracorporeal Photopheresis; Biological · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 12 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois

Conditions: Gastric Cancer
Interventions: Bemarituzumab, Placebo, Modified FOLFOX6; Biological · Drug
Lead sponsor: Five Prime Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 29
States / cities: Tucson, Arizona • Greenbrae, California • Sacramento, California + 23 more

Conditions: HIV Infections
Interventions: Unity in Diversity; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Low Back Pain
Interventions: MBM, VNSM; Behavioral · Device
Lead sponsor: Florida State University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Progressive Multiple Sclerosis, Fatigue
Interventions: N-acetyl cysteine, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells; Biological
Lead sponsor: H. Kim Lyerly; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Durham, North Carolina

Conditions: Urothelial Cancer, Urinary Bladder Neoplasms
Interventions: Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil, Mitomycin C, Gemcitabine, Pembrolizumab; Drug · Radiation
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 21
States / cities: Little Rock, Arkansas • Santa Barbara, California • Aurora, Colorado + 18 more

Conditions: Type 2 Diabetes Mellitus
Interventions: WB-010, WB-011, Placebo; Other
Lead sponsor: Pendulum Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Torrance, California • Tustin, California • Youngstown, Ohio + 2 more

Conditions: Multiple Pulmonary Emboli
Interventions: Low-Dose IV Contrast, Siemens Sensation 64-MDCT scanner., Visipaque 320 non-ionic isoosmolar contrast agent; Procedure · Device · Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Critical Limb Ischemia
Interventions: RJX, Placebo; Drug
Lead sponsor: Reven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Myeloid Leukemia
Interventions: nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more

Conditions: Metachromatic Leukodystrophy
Interventions: Enriched Hematopoetic Stem Cell Infusion; Biological
Lead sponsor: Talaris Therapeutics Inc.; Industry
Eligibility: Female only
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Opioid Misuse, Opioid-Related Disorders, Pharmacist-Patient Relations
Interventions: Patient Navigation, Standard Medication Counseling (SMC); Behavioral · Other
Lead sponsor: Jerry Cochran; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Daridorexant 10 mg, Daridorexant 25 mg; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: COVID-19
Interventions: abatacept infusion, Placebo group; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 82
States / cities: Birmingham, Alabama • Tucson, Arizona • Davis, California + 58 more

Conditions: Metastatic Prostate Cancer
Interventions: Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up; Drug · Radiation · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Surgery
Interventions: Bevonescein, Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay, Intra-operative Visualization using White Light Reflectance (WLR); Drug · Other
Lead sponsor: Alume Biosciences, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Peripheral T-Cell Lymphoma
Interventions: E7777; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Skokie, Illinois • Morristown, New Jersey

Conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
Interventions: Pembrolizumab, Quality-of-Life Assessment, Computed Tomography, Biospecimen Collection; Biological · Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Search by objective public record fields.

A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule

A Developmental Framework For Linking Phonological And Morpho-syntactic Sequential Pattern Rules In DLD: Production

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Detecting Compartment Syndrome Pain in the Presence of Regional Anesthesia in Healthy Volunteers

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

A Network Intervention for Reducing Sexual Risk for HIV With African American Men Who Have Sex With Men (AA MSM)

MBM and taVNS for Low Back Pain and Depressive Symptoms

A Study of Oxidative Pathways in MS Fatigue

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes

Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli

A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Single Patient Expanded Access Protocol: Metabolic Boost

Healthy Opioid Prescription Engagement

A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery

A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study